Oncternal Therapeutics Stock Today
| ONCT Stock | USD 0.69 0.06 8.00% |
Performance0 of 100
| Odds Of DistressOver 60
|
Oncternal Therapeutics is selling for under 0.69 as of the 30th of November 2024; that is 8 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 0.66. Oncternal Therapeutics has more than 60 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for Oncternal Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of September 2024 and ending today, the 30th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 3rd of February 2004 | Category Healthcare | Classification Health Care |
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company has 2.96 M outstanding shares of which 14.21 K shares are now shorted by private and institutional investors with about 0.09 trading days to cover. More on Oncternal Therapeutics
Moving against Oncternal Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Oncternal Stock Highlights
| Thematic Idea | Biotech (View all Themes) | |||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Biotech, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
Debt LevelsOncternal Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Oncternal Therapeutics' financial leverage. It provides some insight into what part of Oncternal Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
Oncternal Therapeutics (ONCT) is traded on NASDAQ Exchange in USA. It is located in 12230 El Camino Real, San Diego, CA, United States, 92130 and employs 27 people. Oncternal Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.21 M. Oncternal Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 2.96 M outstanding shares of which 14.21 K shares are now shorted by private and institutional investors with about 0.09 trading days to cover.
Oncternal Therapeutics currently holds about 78.9 M in cash with (32.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.48, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Oncternal Therapeutics Probability Of Bankruptcy
Ownership AllocationOncternal Therapeutics holds 9.23 pct. of its outstanding shares held by insiders and 12.07 pct. owned by third-party entities.
Check Oncternal Ownership Details
Oncternal Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Wells Fargo & Co | 2024-06-30 | 300 | |
| North Star Investment Management Corp | 2024-09-30 | 250 | |
| Bnp Paribas Arbitrage, Sa | 2024-06-30 | 182 | |
| Advisor Group Holdings, Inc. | 2024-06-30 | 150 | |
| U.s. Bancorp | 2024-06-30 | 100.0 | |
| Ubs Group Ag | 2024-06-30 | 100.0 | |
| Bank Of America Corp | 2024-06-30 | 22.0 | |
| Steward Partners Investment Advisory, Llc | 2024-06-30 | 15.0 | |
| Lindbrook Capital, Llc | 2024-09-30 | 15.0 | |
| Vanguard Group Inc | 2024-09-30 | 139.9 K | |
| Millennium Management Llc | 2024-06-30 | 102.9 K |
Oncternal Therapeutics Historical Income Statement
Oncternal Stock Against Markets
Oncternal Therapeutics Corporate Management
| Pablo Urbaneja | Senior Development | Profile | |
| Anita Wiseth | Senior Resources | Profile | |
| Gunnar Kaufmann | Chief Officer | Profile | |
| Chase JD | General Secretary | Profile | |
| Salim MD | Chief Officer | Profile | |
| Chase Leavitt | General Secretary | Profile | |
| Steven Hamburger | VP Assurance | Profile |
Additional Tools for Oncternal Stock Analysis
When running Oncternal Therapeutics' price analysis, check to measure Oncternal Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncternal Therapeutics is operating at the current time. Most of Oncternal Therapeutics' value examination focuses on studying past and present price action to predict the probability of Oncternal Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncternal Therapeutics' price. Additionally, you may evaluate how the addition of Oncternal Therapeutics to your portfolios can decrease your overall portfolio volatility.